Literature DB >> 35764207

Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China.

Haisu Yi1, Qian Wang1, Jiankai Deng2, Hengchun Li3, Yingkun Zhang4, Zhilong Chen5, Tianxin Ji6, Wenming Liu7, Xuehua Zheng7, Qinghua Ma2, Xinxin Sun7, Yudi Zhang3, Xuegao Yu2, Mengzhang He6, Ling Chen8, Ying Feng9.   

Abstract

Human adenoviruses type 26 (HAdV26) and type 35 (HAdV35) have increasingly become the choice of adenovirus vectors for vaccine application. However, the population pre-existing immunity to these two adenoviruses in China, which may reduce vaccine efficacy, remains largely unknown. Here, we established micro-neutralizing (MN) assays to investigate the seroprevalence of neutralizing antibodies (nAbs) against HAdV26 and HAdV35 in the general population of Guangdong and Shandong provinces, China. A total of 1184 serum samples were collected, 47.0% and 15.8% of which showed HAdV26 and HAdV35 nAb activity, respectively. HAdV26-seropositive individuals tended to have more moderate nAbs titers (201-1000), while HAdV35-seropositive individuals appeared to have more low nAbs titers (72-200). The seropositive rates of HAdV26 and HAdV35 in individuals younger than 20 years old were very low. The seropositive rates of HAdV26 increased with age before 70 years old and decreased thereafter, while HAdV35 seropositive rates did not show similar characteristics. Notably, the seropositive rates and nAb levels of both HAdV26 and HAdV35 were higher in Guangdong Province than in Shandong Province, but did not exert significant differences between males and females. The seroprevalence between HAdV26 and HAdV35 showed little correlation, and no significant cross-neutralizing activity was detected. These results clarified the characteristics of the herd immunity against HAdV26 and HAdV35, and provided information for the rational development and application of HAdV26 and HAdV35 as vaccine vectors in China.
Copyright © 2022 The Authors. Publishing services by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Guangdong and shandong provinces; Human adenovirus type 26 (HAdV 26); Human adenovirus type 35 (HAdV 35); Neutralizing antibody (nAb); Seroprevalence

Mesh:

Substances:

Year:  2022        PMID: 35764207      PMCID: PMC9583180          DOI: 10.1016/j.virs.2022.06.006

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   6.947


  52 in total

1.  Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines.

Authors:  Miguel Aste-Amézaga; Andrew J Bett; Fubao Wang; Danilo R Casimiro; Joseph M Antonello; Deepa K Patel; Elayne C Dell; Laura L Franlin; Nancy M Dougherty; Philip S Bennett; Helen C Perry; Mary-Ellen Davies; John W Shiver; Paul M Keller; Mark D Yeager
Journal:  Hum Gene Ther       Date:  2004-03       Impact factor: 5.695

2.  Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China.

Authors:  Xingui Tian; Zaixue Jiang; Qiang Ma; Qian Liu; Xiaomei Lu; Wenkuan Liu; Xiaohong Liao; Rong Zhou; Xiaobo Su; Qingming Luo
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

3.  Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.

Authors:  Bin Yu; Yan Zhou; Hao Wu; Zhen Wang; Yang Zhan; Xiao Feng; Ranshen Geng; Yongge Wu; Wei Kong; Xianghui Yu
Journal:  J Med Virol       Date:  2012-09       Impact factor: 2.327

4.  Human adenovirus: Viral pathogen with increasing importance.

Authors:  B Ghebremedhin
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-03-14

5.  A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.

Authors:  Nadine C Salisch; Kathryn E Stephenson; Kristi Williams; Freek Cox; Leslie van der Fits; Dirk Heerwegh; Carla Truyers; Marrit N Habets; Diane G Kanjilal; Rafael A Larocca; Peter Abbink; Jinyan Liu; Lauren Peter; Carlos Fierro; Rafael A De La Barrera; Kayvon Modjarrad; Roland C Zahn; Jenny Hendriks; Conor P Cahill; Maarten Leyssen; Macaya Douoguih; Johan van Hoof; Hanneke Schuitemaker; Dan H Barouch
Journal:  Ann Intern Med       Date:  2021-02-16       Impact factor: 25.391

6.  Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China.

Authors:  Xiang Wang; Man Xing; Chao Zhang; Yong Yang; Yudan Chi; Xinying Tang; Hongbo Zhang; Sidong Xiong; Luogang Yu; Dongming Zhou
Journal:  Emerg Microbes Infect       Date:  2014-05-07       Impact factor: 7.163

Review 7.  Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy.

Authors:  Brennetta J Crenshaw; Leandra B Jones; Courtnee' R Bell; Sanjay Kumar; Qiana L Matthews
Journal:  Biomedicines       Date:  2019-08-19

Review 8.  Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention.

Authors:  Joseph P Lynch; Adriana E Kajon
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

9.  Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.

Authors:  Denis Y Logunov; Inna V Dolzhikova; Olga V Zubkova; Amir I Tukhvatullin; Dmitry V Shcheblyakov; Alina S Dzharullaeva; Daria M Grousova; Alina S Erokhova; Anna V Kovyrshina; Andrei G Botikov; Fatima M Izhaeva; Olga Popova; Tatiana A Ozharovskaya; Ilias B Esmagambetov; Irina A Favorskaya; Denis I Zrelkin; Daria V Voronina; Dmitry N Shcherbinin; Alexander S Semikhin; Yana V Simakova; Elizaveta A Tokarskaya; Nadezhda L Lubenets; Daria A Egorova; Maksim M Shmarov; Natalia A Nikitenko; Lola F Morozova; Elena A Smolyarchuk; Evgeny V Kryukov; Vladimir F Babira; Sergei V Borisevich; Boris S Naroditsky; Alexander L Gintsburg
Journal:  Lancet       Date:  2020-09-04       Impact factor: 202.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.